Q2 deal activity points to potential 'bumper year' for pharma — report
High-dollar deals in the second quarter and hungry pharmas looking to fill gaps in their pipelines are “raising hopes for a bumper year,” Evaluate Vantage said in its dealmaking report released during the 2023 BIO conference.
However, the “FTC baring its teeth in an expanded remit may squash them entirely,” the report states.
M&A is off to a strong start following a year of falling stock prices and tough decisions as companies sought to conserve capital. Investment-banking firm Torreya called it a “blistering pace,” with highlights including Pfizer’s $43 billion Seagen deal, Merck’s $10.8 billion Prometheus deal, and GSK’s $2 billion Bellus Health deal. Despite what it called “lackluster” activity in 2022, PwC predicted at the end of last year that dealmaking in 2023 will “more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.